Fig. 3From: Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosineAPN expression levels in various types of cell lines. Tumor cells were grown to 90Â % confluent and HUVECs was grown to 50Â % and 90Â % confluent. Cells were probed with anti-APN antibody (WM15) and then with secondary antibody conjugated with Alexa488. The levels of APN expression for all cell lines were analyzed by flow cytometry. At least three repeats were performed with similar resultsBack to article page